77%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
77%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
77%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
77%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
REVOLUTION Medicines Inc
Closed
SectorHealthcare
37.9 -1.3
Overview
Share price change
24h
Min
37.84
Max
38.1
Income | -19M -213M |
|---|---|
EPS | -1.13 |
Profit margin | -74.379 |
Employees | 616 |
EBITDA | -24M -237M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +86.43% upside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | -754M 6.8B |
|---|---|
Previous open | 39.2 |
Previous close | 37.9 |
News Sentiment
By Acuity
50%
50%
131 / 376 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
REVOLUTION Medicines Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
REVOLUTION Medicines Inc Forecast
Price Target
By TipRanks
86.43% upside
12 Months Forecast
Average 70.88 USD 86.43%
High 80 USD
Low 57 USD
Based on 9 Wall Street analysts offering 12 month price targets forREVOLUTION Medicines Inc - Dist in the last 3 months.
Sentiment
By Acuity
131 / 376 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About REVOLUTION Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
